12:00 AM
 | 
Mar 20, 2000
 |  BC Week In Review  |  Clinical News  |  Regulatory

Antisense inhibitors regulatory update

HYBN received U.S. Patent No. 5,968,909 and European Patent No. EP0850300...

Read the full 33 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >